Clinical Computing PLC
15 February 2002
For Immediate Release 15 February 2002
CLINICAL COMPUTING PLC: CONTRACT GAINS FOR
CLINICAL VISION PRODUCT AND DATE FOR NEXT FINAL RESULTS
Clinical Computing Plc ('CCL'), which produces leading clinical software
systems, announces that it will report its final results for the year ended 31
December 2001, on Monday, 25th March 2002. At that time, it will expect to
report turnover for that year in the order of £2.1m.
CCL also announces the following contract gains in the United States, amounting
to $US728,000 (£515,000), from its new Clinical Vision product for the renal
dialysis and transplant markets. These contracts will be recognized in CCL's
current financial year ending 31 December 2002.
The contract gains are from:
Flushing Hospital, Flushing, New York
A single site installation with plans to expand into a second site.
Cabell Huntington Hospital, Huntington, West Virginia
A newly renovated single site dialysis unit.
Middletown Regional Hospital, Middletown, Ohio
A newly constructed dialysis unit.
The Health Alliance, Cincinnati, Ohio
The combination of The Christ Hospital, The University Hospital, The St. Luke
Hospitals, Jewish Kenwood Hospital and Fort Hamilton Hughes Hospital, all
located in the greater Cincinnati area.
The hospitals will serve as strategic site for Clinical Computing's United
States sales operation, also located in Cincinnati. In addition, The University
Hospital has purchased the Clinical Vision transplant solution and will soon
integrate both the renal and transplant solutions on one common platform.
Dialysis Centres of Lincoln, Lincoln, Nebraska
Operates 4 dialysis centres in Nebraska and is a current customer utilising
Clinical Computing's RENLStar software.
The above contracts will also deliver $125,000 of new annual maintenance fees to
CCL in addition to the fees noted above.
Commenting, Jack Richardson, Chief Executive Officer, Clinical Computing Plc,
said:
'These contract gains, with respected facilities, validates our strategy and
efforts of the past two years to develop Clinical Vision for multiple clinical
markets while extending our company presence in both the renal dialysis and
transplant markets. We are now positioned to demonstrate Clinical Vision's
capabilities in clinical areas that we previously did not market. The US
transplant market alone is estimated at $28 million.'
ENDS
For further information please contact:
Jack Richardson, Chief Executive, Clinical Computing Plc Tel: 001513 651 3803
Joe Marlovits, Finance Director, Clinical Computing Plc Tel: +44 (0)20 8380 4400
Peter Binns/Paul McManus, Binns & Co PR Ltd Tel: +44 (0)20 7786 9600
This information is provided by RNS
The company news service from the London Stock Exchange
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.